论文部分内容阅读
目的:评价雷帕霉素药物洗脱支架治疗冠心病并血小板高度活化状态冠状动脉狭窄的疗效。方法:回顾202例冠心病患者行冠状动脉内支架介入治疗,其中131例为冠心病并血小板高度活化状态,采用雷帕霉素药物洗脱支架治疗62例,采用普通支架治疗69例;71例为冠心病不伴血小板高度活化状态,均为雷帕霉素药物洗脱支架治疗。结果:随访12个月,冠心病并血小板高度活化状态雷帕霉素药物洗脱支架治疗组,心脏事件发生率8.06%,普通支架治疗组心脏事件发生率10.14%,2组比较差异有统计学意义(P<0.01)。血小板高度活化状态冠状动脉再狭窄率比较,雷帕霉素药物洗脱支架治疗组11.29%,普通支架治疗组15.94%,2组比较差异有统计学意义(P<0.01)。结论:雷帕霉素药物洗脱支架能有效防止血小板高度活化状态冠状动脉病变新生内膜增殖和再狭窄,提高冠状动脉支架术的成功率,降低心脏事件发生率。
OBJECTIVE: To evaluate the efficacy of rapamycin eluting stent in the treatment of coronary heart disease and coronary artery stenosis in patients with highly activated platelets. Methods: A retrospective study of 202 patients with coronary artery disease interventional coronary intervention, including 131 cases of coronary heart disease and high platelet activation, the use of rapamycin-eluting stent treatment of 62 cases, the use of ordinary stent treatment of 69 cases; 71 cases Coronary heart disease is not associated with highly activated platelets, are rapamycin-eluting stent treatment. Results: After 12 months of follow-up, coronary heart disease and platelet-activated rapamycin-eluting stent group, the incidence of cardiac events was 8.06%, and the incidence of cardiac events in general stent group was 10.14%. There were statistically significant differences between the two groups Significance (P <0.01). The rate of restenosis of coronary arteries in highly activated platelet count was 11.29% in the rapamycin-eluting stent group and 15.94% in the conventional stent group, with significant difference between the two groups (P <0.01). Conclusion: The rapamycin-eluting stent can effectively prevent neointimal hyperplasia and restenosis in platelet-activated coronary artery lesion, improve the success rate of coronary stenting and reduce the incidence of cardiac events.